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IntroductIon
Skin and soft-tissue infections (SSTIs) are commonly observed and differ in terms of site and 
localization, clinical characteristics, and the aetiological agent; these infections are usually 
caused by Staphylococcus aureus or beta-haemolytic streptococci, and are the most frequent 
forms of methicillin-resistant S. aureus (MRSA) infections. SSTIs are considered complicated 
if they involve deeper skin structures (fascia or muscle layers), require significant surgical 
intervention or arise in the presence of significant co-morbidity. The progressive increase of 
bacterial resistance, in particular for Gram-positive bacteria infections, to currently used agents 
is a serious and growing problem, and in particular MRSA, GISA (glycopeptides-insusceptible 
S. aureus), VRE and GRE (glycopeptides-resistant enterococci) are of concern. There is, 
therefore, a need for additional agents active against these difficult-to-treat pathogens.
IndIcatIons and dosIng
Daptomycin (DPT) is a novel macrocyclic lipopeptide antibiotic for the treatment of complicated 
skin and soft-tissues infections caused by multi-resistant gram-positive bacteria. The drug is 
derived from a natural product of Streptomyces roseosporus, and is active against methicillin-
resistant staphylococci and vancomycin-resistant enterococci. Recently, DPT obtained the 
indication for Staphylococcus aureus bacteraemia (SAB) when associated with right-sided 
infective endocarditis (RIE) or with SSTIs, and for RIE due to Staphylococcus aureus. DPT is 
approved at the recommended dose of 4 mg/kg for SSTIs and at a higher dose for bacteraemia 
or endocarditis (6 mg/kg), and must be administered as a single daily dose for 7-14 days or 
until the infection is resolved. The drug is active against Gram-positive bacteria only; if mixed 
infection (Gram-negative or anaherobic bacteria) is suspected, it should be co-administred with 
appropriate antibacterial agents. This drug is currently included by AIFA (Agenzia Italiana del 
Farmaco) in a drug efficacy and safety monitoring program.
PharmacokInetIcs
DPT is prevalently excreted by the kidneys: therapeutic response and renal function should 
be closely monitored in patients with renal insufficiency, and dosage adjustment is needed if 
Ccr is less than 30 ml/min. There is no evidence of hepatic metabolism with involvement of 
CYP450 enzymes, or of biological activity for metabolites.
PharmacodynamIcs
DPT exerts its antibiotic action by inserting into the cytoplasmic membrane of Gram-positive 
bacterial cells and causing the dissipation of membrane electrical potential, which results in 
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absorption and distribution
cmax tmax Binding to plasma proteins Volume of distribution
54.6 mg/l (10.0) 0.5 (0.5) h 90-95% 0.093 (12.1) l/kg
elimination
systemic 
clearance
Plasma terminal  
half-life
elimination Interactions 
9.6 (13.5) ml/h/kg 7.4 (12.3) h 78% urine, 5.7% faeces HMG-CoA reductase 
inhibitors, tobramycin
table I
Mean (%CV) value for absorption, distribution, metabolism and elimination of DPT after administration of a 
single dose
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bacterial cell death. Bactericidal activity is concentration-dependent against S. aureus and 
vancomycin-resistant enterococci; there is also a concentration-dependent post-antibiotic 
affect against E. faecalis and S. aureus. 
effIcacy and safety 
Efficacy and safety of DPT in SSTIs were compared with those of conventional antibiotics 
in two pivotal studies having similar but not identical design, including patients with SSTIs 
suspected to be due to Gram+ bacteria. One of them was conducted in USA and South 
Africa, and the other prevalently in European countries. 
The appropriate comparator (penicillase-resistant penicillins or vancomycin) was choosed 
prior to randomization; both protocols provided for a switch to oral medication when certain 
criteria were met, and the duration of iv therapy was 7 to 14 days, extensible on demand. 
Population for analysis was distinguished in ITT (Intent-To-Treat, all the treated population 
with SSTIs), MITT (Modified Intent-To-Treat, patients infected with a Gram+ pathogen), and 
study design comparator
efficacy  
(% clinical success) 
safety
DAP-SST-9801 547 patients with 
diagnosis of SSTIs. 
Multicenter (USA + South 
Africa), randomized 1:1, 
single-blind study
DPT 4 mg/kg once daily (265 pt)
vs SSP* (4-12 g iv once daily) 
or VNC (1 g iv every 12 h)
MITT: 67% DPT (N = 209), 
67% COMP (N = 212)
CE: 75% DPT (N = 140),  
75% COMP (N = 142)
20% pt in DPT group 
and 19% in the 
comparative group had 
drug-related adverse 
effects (in both groups: 
7% gastrointestinal 
disorders, 2% nausea 
or diarrhea, 1% vomit or 
constipation)
DAP-SST-9901 571 patients with 
diagnosis of SSTIs. 
Multicenter (39 European 
sites), randomized 1:1, 
single-blind study
DPT 4mg/kg once daily (269 pt)
vs SSP* (4-12 g iv once daily) 
or VNC (1g iv every 12 h)
MITT: 84.5% DPT (N = 140), 
83.9% COMP (N = 142)
CE: 88.6% DPT (N = 209),  
89.7% COMP (N = 212)
table II
Summary of main studies investigating efficacy and safety of daptomycin in patients with skin or soft-tissues infections
 * nafcillin, cloxacillin, fluxloxacillin or oxacillin
 CE = clinically evaluable population; COMP = comparator; DPT = daptomycin; MITT = Modified Intent-To-Treat population; 
SSP = penicillase-resistant penicillins; VNC = vancomycin
ex-factory  
price (€)
Daily price (€)
min max
Ampicillin + Sulbactam 2.62 2.62 10.46
Cefazolin (1 vial) 1.13 1.13 3.40#
Cloxacillin 0.82 6.53 19.58
Daptomycin 101.55 56.87 56.87
Flucloxacillin (100 vial) 180.61 7.22 21.67
Levofloxacin 24.62 12.31 49.25
Linezolid (10 vial) 548.41 109.68 109.68#
Meropenem (10 vial) 256.22 38.43 76.87
Oxacillin 1.80 7.20 21.59
Piperacillin/tazobactam 17.11 17.11 68.43
Quinupristin/dalfopristin 47.20 141.61 141.61#
Teicoplanin 24.96 24.96 49.92
Tigecycline (10 vial) 486.45 97.29 145.94*#
Vancomycin (1 vial) 5.15 20.59 20.59
table III
Daily pharmaceutical costs for different available therapies for SSTIs treatment [Informatore Farmaceutico 2008]
 * only for 1st day of therapy
 # price neglects further negotiated discount on supplies for NHS
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CE (Clinically Evaluable, all treated patients for whom the clinical outcome reflected the effect 
of the study compound): CE patients can be judged as clinical successes if they resulted as 
cured (return to the pre-infection baseline, with resolution of clinical signs and symptoms) or 
improved (partial resolution of the infection and no need of further antibacterial therapy) after 
receiving the study medication for at least 4 days, and having not received other antibiotics. 
The primary objective was to demonstrate non-inferiority of DPT, reached if the difference in 
success rates between treatment groups was less than 10%. 
Results showed that success rates were numerically similar between the two treatments, and 
also comparable in sub-groups (severe infection, surgical intervention, bacteraemia), but 
lower for DPT-treated patients in the subgroup with over 65 years. Duration of therapy resulted 
lower in DPT-treated patients (63% versus 33% required only 4-7 days of therapy, p<0,0001). 
Safety also appeared comparable between DPT and conventional therapy, whereas a rapid 
elevation in CPK levels was seen in 2.1% of DPT and only in 1.4% of comparator-treated 
patients. Skeletal muscle toxicity (seen in early studies), renal risk and the use of this drug 
in aged population (where an higher incidence of adverse effects has been seen) will be 
monitored in further studies.
economIc eValuatIons
We found only one analysis assessing cost outcomes associated with the use of DPT in SSTIs; 
this study, performed by Fossaceca and colleagues in 2007, analyzed the first 50 inpatients 
treated with DPT in USA, and found an average cost of $ 727 for DPT course, reduced to 
only $ 287 in patients who did not respond to prior antibiotic treatment for a Gram-positive 
bacterial infection. In patients with renal insufficiency the mean cost is $ 390, and for patient 
transitioned to outpatient therapy hospital charges were reduced by an estimated $ 102,340. 
Infection was resolved with DPT therapy in 96% of patients; cost savings were determined 
essentially by early identification of antibiotic failure, first-line use of DPT in patients with SSTIs 
and outpatient therapy. 
In Table III we calculated daily pharmaceutical costs of available therapies for SSTIs treatment. 
For each formulation we valorized minimum and maximum dosing (from the SPCs or 
from reference trials), using retail price deduced from Informatore Farmaceutico 2008: we 
considered always an ex-factory price. For packages with identical price, we considered the 
less costly one. This is not to be intended as a cost-minimization analysis, but as a simple 
overlook of currently available treatments. 
Name of the Medicinal Product Cubicin 
Marketing Authorisation Holder Novartis Europharm Ltd
Active Substance Daptomycin
Pharmaco-therapeutic Group Antibacterials for systemic use, Other antibacterials 
ATC Code J01XX09 
Date of issue of Marketing Authorisation valid 
throughout the European Union 
19 January 2006
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